CorMedix Inc. (CRMD)
CRMD moved a median of -0.42% 30 minutes after news, and -0.29% by the close. How CRMD actually reacts to news — the realized, point-in-time move the market made, measured across 269 labeled events over the last three years with zero look-ahead.
CRMD’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.22% | 41% | 268 |
| 30-min | -0.42% | 39% | 268 |
| 60-min | -0.35% | 42% | 268 |
| to close | -0.29% | 43% | 267 |
| Middle 50% of CRMD reactions | -1.86% to +0.69% |
|---|---|
| Median reaction (30-min) | -0.42% |
| Measured reactions | 269 |
Half of all CorMedix Inc. news events land between -1.86% and +0.69% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CRMD reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | -0.09% | 40% | +1.24% |
| Coverage initiations | 12 | +0.86% | 75% | +2.58% |
| Rating reiterations | 75 | -0.34% | 40% | -0.93% |
| Price-target raises | 10 | -0.18% | 40% | +1.09% |
| Price-target cuts | 10 | +0.51% | 80% | +0.05% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how CRMD ranks against every other measured name →
That’s how CRMD usually reacts — get an email when it moves on news →Email me when CRMD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CRMD's baseline. Nothing else.
Recent CRMD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference | Press release | GlobeNewswire | -0.24% | +1.58% | |
| Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.36% | -3.10% | |
| Form 10-Q CorMedix Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.36% | -3.10% | |
| Form 8-K CorMedix Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.36% | -3.10% | |
| Form 8-K CorMedix Inc. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +0.41% | — | |
| CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026 | Press release | GlobeNewswire | -0.41% | -2.31% | |
| Form 8-K CorMedix Inc. For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | -0.17% | +1.15% | |
| Form 8-K CorMedix Inc. For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +1.56% | +6.01% | |
| Form S-8 POS CorMedix Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.52% | +1.95% | |
| Form 8-K CorMedix Inc. For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | -1.07% | -8.31% | |
| Form 8-K CorMedix Inc. For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | -0.25% | +1.06% | |
| U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation | Press release | GlobeNewswire | -0.25% | +1.06% | |
| Cormedix Therapeutics to Participate in two Upcoming Investor Conferences | Press release | GlobeNewswire | +0.88% | -5.27% | |
| Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -4.48% | -7.68% | |
| Form 10-Q CorMedix Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -4.48% | -7.68% | |
| Form 8-K CorMedix Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -4.48% | -7.68% | |
| CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026 | Press release | GlobeNewswire | -0.19% | -2.15% | |
| Form ARS CorMedix Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.09% | +0.66% | |
| Form DEF 14A CorMedix Inc. For: Jun 23 | SEC filing · Form DEF | SEC EDGAR | +0.09% | +0.66% | |
| Form DEFA14A CorMedix Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.09% | +0.66% | |
| CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients | Press release | GlobeNewswire | +0.13% | +3.85% | |
| Form 8-K CorMedix Inc. For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | +0.13% | +3.85% | |
| Form PRE 14A CorMedix Inc. For: Apr 17 | SEC filing · Form PRE | SEC EDGAR | -0.07% | +3.55% | |
| CorMedix to Participate in Needham Virtual Healthcare Conference | Press release | GlobeNewswire | -0.21% | +0.28% | |
| Form 8-K CorMedix Inc. For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | +3.50% | +4.46% | |
| CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -1.89% | -0.79% | |
| Form 10-K CorMedix Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.89% | -0.79% | |
| Form 8-K CorMedix Inc. For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | -1.89% | -0.79% | |
| CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026 | Press release | GlobeNewswire | -0.29% | +3.44% | |
| CorMedix to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.40% | -1.74% | |
| CorMedix Therapeutics Announces Share Repurchase Program | Press release | GlobeNewswire | +3.28% | +0.99% | |
| CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026 | Press release | GlobeNewswire | +0.50% | +2.69% | |
| CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +5.31% | +0.26% | |
| CorMedix Therapeutics Announces Leadership and Board Updates | Press release | GlobeNewswire | +1.11% | -12.57% | |
| CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates | Press release | GlobeNewswire | +1.11% | -12.57% | |
| Form 8-K CorMedix Inc. For: Jan 05 | SEC filing · Form 8-K | SEC EDGAR | +1.11% | -12.57% | |
| CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath | Press release | GlobeNewswire | +2.03% | +3.02% | |
| CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance | Press release | GlobeNewswire | -6.82% | -3.79% | |
| Form 10-Q CorMedix Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -6.82% | -3.79% | |
| Form 8-K CorMedix Inc. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -6.82% | -3.79% | |
| CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025 | Press release | GlobeNewswire | -0.89% | -5.84% | |
| Form DEF 14A CorMedix Inc. For: Nov 10 | SEC filing · Form DEF | SEC EDGAR | +1.19% | -1.50% | |
| CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath | Press release | GlobeNewswire | -1.33% | +0.53% | |
| Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their Rights | Press release | Business Wire | -1.33% | +0.53% | |
| CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance | Press release | GlobeNewswire | -2.63% | +3.23% | |
| Form 8-K CorMedix Inc. For: Oct 20 | SEC filing · Form 8-K | SEC EDGAR | -2.63% | +3.23% | |
| Form PRER14A CorMedix Inc. | SEC filing · Form PRER14A | SEC EDGAR | +0.47% | +0.38% | |
| Form RW CorMedix Inc. | SEC filing · Form RW | SEC EDGAR | +1.08% | +1.08% | |
| Form S-3ASR CorMedix Inc. | SEC filing · Form S-3ASR | SEC EDGAR | +1.08% | +1.08% | |
| Form RW CorMedix Inc. | SEC filing · Form RW | SEC EDGAR | +0.35% | +1.94% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CRMD section they belong to.
Where else CRMD is measured.
CRMD earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| PRESBIA PLC ORDINARY SHARES (LENS) | 270 | 0.00% | 42% |
| Achieve Life Sciences, Inc. - Common Shares (ACHV) | 269 | -0.54% | 42% |
| Verrica Pharmaceuticals Inc. (VRCA) | 269 | -0.01% | 46% |
| CONMED Corporation (CNMD) | 268 | -0.11% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is CorMedix Inc.'s median reaction calculated?
Every labeled CRMD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 269 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of CRMD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CRMD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.